国际共识:年轻特纳综合征患者的卵巢组织冷冻保存——一项包含16国55名专家的伦理德尔菲研究结果
该研究采用三轮伦理德尔菲法,于2018年2月至12月间系统征询了来自16个国家的55名专家(包括妇科医生、内分泌医生、伦理学家和患者代表),就年轻特纳综合征(TS)患者卵巢组织冷冻保存(OTC)的获益与风险进行匿名评分与反馈。专家最终就8项关键声明达成共识,其中96%的参与者认为应为年轻TS女性提供OTC,但须先限于安全可控的研究环境,并配合充分的咨询与知情同意程序。
要点
- 专家共识认为年轻TS女性可接受OTC,但仅限严格条件(安全可控的研究环境、充分咨询与知情同意)下提供。
- 96%的专家赞成在常规护理前,先于研究环境中提供OTC。
- 需要开展聚焦有效性与安全性的长期随访协作研究,并建议建立国际登记系统。
核心结论
- 专家小组声明:应为年轻TS女性提供OTC,但仅在严格条件下进行。
- 多数专家(96%)认为OTC应先限于安全可控的研究环境,配合充分咨询与知情同意后再纳入常规护理。
研究设计与样本
- 研究类型为三轮伦理德尔菲研究,于2018年2月至12月进行。
- 参与专家共55名,包括12名妇科医生、13名(儿科)内分泌医生、10名医学伦理学家和20名患者代表,来自16个国家。
主要发现
- 第一轮有46名参与者完成(应答率84%),基于严格标准筛选出6项关键声明并舍弃13项。
- 剩余19项声明及专家小组提交的2项额外声明在第二轮由41名参与者(应答率75%)重新评估,分析后新增2项关键声明。
- 最终8项关键声明获批,96%的专家认为应为年轻TS女性提供OTC(先限于研究环境),其余4%未反对但未回复。
关键数值与推荐
- 关键声明筛选基于严格纳入标准,未提供具体阈值。
临床怎么用
- 年轻TS女性可被告知OTC作为实验性生育力保存选项,但应在安全可控的研究环境中提供。
- 提供OTC前须进行充分咨询并执行知情同意程序。
- 建议建立针对TS女性生育力保存程序的国际登记系统。
局限性
- 研究的匿名性质可能导致问责不足。
- 专家选择基于参与意愿,可能引入选择偏倚。
- 并非所有小组成员参与全部轮次,可能导致选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the standpoint of an international expert panel on ovarian tissue cryopreservation (OTC) in young females with Turner syndrome (TS)? SUMMARY ANSWER: The expert panel states that OTC should be offered to young females with TS, but under strict conditions only. WHAT IS KNOWN ALREADY: OTC is already an option for preserving the fertility of young females at risk of iatrogenic primary ovarian insufficiency (POI). Offering OTC to females with a genetic cause of POI could be the next step. One of the most common genetic disorders related to POI is TS. Due to an early depletion of the ovarian reserve, most females with TS are confronted with infertility before reaching adulthood. However, before offering OTC as an experimental fertility preservation option to young females with TS, medical and ethical concerns need to be addressed. STUDY DESIGN, SIZE, DURATION: A three-round ethical Delphi study was conducted to systematically discuss whether the expected benefits exceed the expected negative consequences of OTC in young females with TS. The aim was to reach group consensus and form an international standpoint based on selected key statements. The study took place between February and December 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: Anonymous panel selection was based on expertise in TS, fertility preservation or medical ethics. A mixed panel of 12 gynaecologists, 13 (paediatric) endocrinologists, 10 medical ethicists and 20 patient representatives from 16 different countries gave consent to participate in this international Delphi study. In the first two rounds, experts were asked to rate and rank 38 statements regarding OTC in females with TS. Participants were offered the possibility to adjust their opinions after repetitive feedback. The selection of key statements was based on strict inclusion criteria. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 46 participants completed the first Delphi round (response rate 84%). Based on strict selection criteria, six key statements were selected, and 13 statements were discarded. The remaining 19 statements and two additional statements submitted by the expert panel were re-evaluated in the second round by 41 participants (response rate 75%). The analysis of the second survey resulted in the inclusion of two additional key statements. After the approval of these eight key statements, the majority of the expert panel (96%) believed that OTC should be offered to young females with TS, but in a safe and controlled research setting first, with proper counselling and informed consent procedures, before offering this procedure in routine care. The remaining participants (4%) did not object but did not respond despite several reminders. LIMITATIONS, REASONS FOR CAUTION: The anonymous nature of this study may have led to lack of accountability. The selection of experts was based on their willingness to participate. The fact that not all panellists took part in all rounds may have resulted in selection bias. WIDER IMPLICATIONS OF THE FINDINGS: This international standpoint is the first step in the global acceptance of OTC in females with TS. Future collaborative research with a focus on efficacy and safety and long-term follow-up is urgently needed. Furthermore, we recommend an international register for fertility preservation procedures in females with TS. STUDY FUNDING/COMPETING INTEREST(S): Unconditional funding (A16-1395) was received from Merck B.V., The Netherlands. The authors declare that they have no conflict of interest.
引用
- Schleedoorn MJ, Mulder BH, Braat DDM, et al. International consensus: ovarian tissue cryopreservation in young Turner syndrome patients: outcomes of an ethical Delphi study including 55 experts from 16 different countries. Hum Reprod. 2020. PMID: 32348471. doi:10.1093/humrep/deaa007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。